Pharma BD Deal Intelligence
Lilly's first move into psychedelic neuroscience; upside gated on 2029 BPL-003 Phase 3 readout
Full analysis, sources & comparables →Eli Lilly agreed to acquire AtaiBeckley Inc., a Nasdaq-listed psychedelic-medicine developer, in a deal announced July 16, 2026. Lilly will pay $6.75 per share in cash (~$2.8B upfront) plus a contingent value right worth up to $2.50 per share tied to development and regulatory milestones, bringing the total potential consideration to approximately $3.8B — the largest psychedelic acquisition to date. The lead asset, BPL-003 (mebufotenin benzoate), is an intranasal synthetic form of 5-MeO-DMT in development for treatment-resistant depression; initial Phase 3 results are expected in 2029. The transaction is subject to customary closing conditions and shareholder approval.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / AtaiBeckley Inc. (this deal) | 2026 | $3.8B | 61 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |